Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin.

about

Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin.

Item

http://www.wikidata.org/entity/Q42290643

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Downregulation of NPM expressi ...... gastric cancer to oxaliplatin.

@en

Downregulation of NPM expressi ...... gastric cancer to oxaliplatin.

@nl

type

Item

label

Downregulation of NPM expressi ...... gastric cancer to oxaliplatin.

@en

Downregulation of NPM expressi ...... gastric cancer to oxaliplatin.

@nl

prefLabel

Downregulation of NPM expressi ...... gastric cancer to oxaliplatin.

@en

Downregulation of NPM expressi ...... gastric cancer to oxaliplatin.

@nl

P1476

Downregulation of NPM expressi ...... gastric cancer to oxaliplatin.

@en

P2093

Aihua Sui

http://www.w3.org/2001/XMLSchema#string

Lu Yue

http://www.w3.org/2001/XMLSchema#string

Qian Tang

http://www.w3.org/2001/XMLSchema#string

Ruyong Yao

http://www.w3.org/2001/XMLSchema#string

Tianjun Li

http://www.w3.org/2001/XMLSchema#string

Yong Li

http://www.w3.org/2001/XMLSchema#string

Yongning Sun

http://www.w3.org/2001/XMLSchema#string

Zan Shen

http://www.w3.org/2001/XMLSchema#string

Zhenni Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Nucleophosmin: from structure and function to disease development

Recent developments and innovations in gastric cancer

Emerging blood-based biomarkers for detection of gastric cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.

Untangling the ErbB signalling network

UV stimulation of nucleophosmin/B23 expression is an immediate-early gene response induced by damaged DNA

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

P304

2377-2384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2017.5722

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28454407

http://www.w3.org/2001/XMLSchema#string

P932

5403240

http://www.w3.org/2001/XMLSchema#string